Is abrdn’s eye-catching 9.2% dividend yield sustainable?

Shares in investment manager abrdn currently yield 9.2%. Generally speaking, says Rupert Hargreaves, it pays to be sceptical of very high dividend yields. So is that the case here, or is abrdn one for income investors to tuck away?

Abrdn plc (LSE: ABDN) currently offers one of the highest dividend yields in the FTSE 100. The company, formerly known as Standard Life Aberdeen plc, yields 8.4% based on Refinitiv analyst estimates.  

It pays to be sceptical of high dividend yields and in this case, there’s clear evidence that this might not be sustainable. The company’s dividend cover – the ratio of earnings per share divided by the dividend payout – stands at 0.7 on a forward basis suggesting the firm is paying out more than it can afford – a clear red flag for income investors.  

That said, dividend cover is a simplistic metric and it’s generally not wise to put too much weight on any one figure. 

So before we get into whether or not the company’s dividend is sustainable, let’s take a step back and look at where revenue comes from. 

Abrdn has been struggling to grow in a competitive market  

Abrdn’s business is, to quote the awful corporat-ese, “structured around three vectors”. These are “investment solutions”, “adviser solutions” and “personal wealth services”.  

Since selling its life assurance, pensions and long-term savings arm in 2018, abrdn has been focusing on growing its wealth management businesses, which tend to have higher profit margins, fewer regulatory constraints and reduced capital requirements.  

Trouble is, wealth management is a highly competitive industry with many giant asset managers around the world all fighting for market share. The London-listed company is up against the likes of American giant Blackrock (NYSE: BLK) and FTSE 100 peer Schroders (LSE: SDR). Both of these firm’s have a wider global reach and a bigger pool of client assets. 

Despite management’s best attempts, abrdn is really struggling to grab market share. AUMA (assets under management and administration) fell to £508bn the first half of 2022, compared with £542bn last year - that’s even after including assets from the group’s recent acquisition of trading platform Interactive Investor (ii). 

The drop was driven largely by the final stage of the withdrawal of Lloyds Bank’s (LSE: LLOY) vast Scottish Widows portfolio. The bank announced that it was pulling this mandate from abrdn in 2018, three years earlier than contracted, due to conflicts of interest. After a lengthy legal spat, abrdn was allowed to continue managing £35bn of the £109bn Scottish Widows portfolio with the rest being split between BlackRock and Schroders. 

Even after stripping out this large outflow, AUMA still dropped overall. 

The dividend may be more affordable than it looks at first glance 

Earlier in this article I mentioned that abrdn’s earnings per share are not enough to cover its dividends, and that’s true – but not on management’s preferred measure of profit.  

The firm’s annual report notes that in 2021 adjusted operating profit totalled £323m (fee income minus expenses) generating adjusted earnings per share of 13.7p against a dividend payout of 14.6p.  

However, adjusted capital generation, which shows how adjusted profit contributes to regulatory capital, totalled £366m for the year. On this basis, the dividend payout is covered 1.2 times. Management sets the dividend based on this figure, not the adjusted operating profit number outlined above.  

If this all seems a little complicated, you’re right – it is. There are lots of moving parts here and to add to the confusion, abrdn also reports its IFRS profit before tax measure, which includes items such as restructuring costs and profit on disposal of interests.  

On this metric, the company earned £1.1bn in 2021 mainly thanks to investment gains on the group’s share of Indian life insurance group HDFC Asset Management and interest in Phoenix (received as part of the sale in 2018).  However, this figure is highly volatile. For the first half of 2022, the group’s IFRS loss before tax amounted to £320m. This reflected losses on abrdn’s listed investments (undoing a chunk of the IFRS profits earned last year). 

Market conditions are also having another impact on the group’s bottom line. As part of its shift towards wealth management, the company has become increasingly reliant on trading and management fee income generated on investors’ assets. As volatility has increased, investors have pulled back, leading to reduced fee income (and the value of their portfolios has declined hitting management fee income). As a result of this double headwind, group fee based revenue slumped 8% during the first half of 2022. 

This soup of numbers might not mean much to all readers, but what it shows is that while abdrn might be making enough money to cover its dividend today, there’s no guarantee this will continue. 

No immediate threat, but it’s hard to tell what happens in the long term 

Overall, I don’t think abrdn’s dividend is really under threat today. The company is generating enough capital to cover the distribution (including asset sales and regulatory capital adjustments) and that’s what matters in the short term.  

It’s the longer term I’m concerned about. Abrdn needs to attract new investors to grow AUMA and fees. It’s not clear it will be able to do that in the highly competitive wealth and fund management industry. It may even have to cut fees charged to clients to remain competitive. 

Analysts appear to agree. Since the beginning of this year the average Refinitiv analyst estimate for 2022 earnings has been revised lower by 30%. With that being the case it’s not really surprising that the stock has fallen 29% over the past six months.

The big question is, if abrdn can’t grow earnings, how will it be able to grow its dividend in the long-run? That’s a question I can’t answer. As such, while I don’t think abrdn’s dividend is at risk of being cut today, I wouldn’t want to add the shares to my portfolio. I think there are other companies out there with better growth prospects and more attractive valuations.  

After all, there’s more to investing than dividends. Capital growth is also a key component of the equation

SEE ALSO:
How to find the best stocks with dividends
Five dividend stocks to beat inflation
The ten highest dividend yields in the FTSE 100

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to solve Britain’s water crisis
UK Economy

How to solve Britain’s water crisis

A drought has been officially declared across much of Britain, despite the fact that climate change is bringing more rain than ever. What’s going wron…
18 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How capitalism has been undermined by poor governance
Global Economy

How capitalism has been undermined by poor governance

Capitalism’s “ruthless efficiency” has been undermined by poor governance, a lack of competition and central banks’ over-enthusiastic money printing, …
18 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022